Dermata Therapeutics (NASDAQ:DRMA) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Dermata Therapeutics (NASDAQ:DRMA) to a sell rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of Dermata Therapeutics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Dermata Therapeutics presently has an average rating of “Hold” and a consensus target price of $10.00.

Dermata Therapeutics Stock Performance

Dermata Therapeutics stock opened at $2.25 on Friday. The firm has a market cap of $2.32 million, a price-to-earnings ratio of -0.29 and a beta of 0.54. Dermata Therapeutics has a 52-week low of $1.58 and a 52-week high of $23.70. The firm has a 50 day moving average price of $2.46 and a two-hundred day moving average price of $4.14.

Dermata Therapeutics (NASDAQ:DRMA) last posted its quarterly earnings data on Friday, November 14th. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.59) by ($0.06).

Dermata Therapeutics Company Profile

Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.

At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques.